Tumoral MGMT content predicts survival in patients with aggressive pituitary tumors and pituitary carcinomas given treatment with temozolomide

D. Bengtsson; H. D. Schrøder; K. Berinder; D. Maiter; C. Hoybye; O. Ragnarsson; U. Feldt-Rasmussen; Rasmussen Krogh Rasmussen; A. van der Lely; M. Petersson; G. Johannsson; M. Andersen; P. Burman

doi:10.1007/s12020-018-1751-9

Tumoral MGMT content predicts survival in patients with aggressive pituitary tumors and pituitary carcinomas given treatment with temozolomide

D. Bengtsson, H. D. Schrøder, K. Berinder, D. Maiter, C. Hoybye, O. Ragnarsson, U. Feldt-Rasmussen, Rasmussen Krogh Rasmussen, A. van der Lely, M. Petersson, G. Johannsson, M. Andersen, P. Burman^*

^*Corresponding author for this work

Research output: Contribution to journal › Journal article › Research › peer-review

Original language	English
Journal	Endocrine
Volume	62
Issue number	3
Pages (from-to)	737–739
ISSN	1355-008X
DOIs	https://doi.org/10.1007/s12020-018-1751-9
Publication status	Published - Dec 2018

Keywords

Adult
Aged
Antineoplastic Agents, Alkylating/therapeutic use
DNA Modification Methylases/metabolism
DNA Repair Enzymes/metabolism
Female
Humans
Male
Middle Aged
Pituitary Neoplasms/drug therapy
Prognosis
Survival Rate
Temozolomide/therapeutic use
Treatment Outcome
Tumor Suppressor Proteins/metabolism

Documents & Links

10.1007/s12020-018-1751-9

Cite this

Bengtsson, D., Schrøder, H. D., Berinder, K., Maiter, D., Hoybye, C., Ragnarsson, O., Feldt-Rasmussen, U., Krogh Rasmussen, R., van der Lely, A., Petersson, M., Johannsson, G., Andersen, M., & Burman, P. (2018). Tumoral MGMT content predicts survival in patients with aggressive pituitary tumors and pituitary carcinomas given treatment with temozolomide. Endocrine, 62(3), 737–739. https://doi.org/10.1007/s12020-018-1751-9

@article{4d9934ebf2994515813cdaa3a5750532,

title = "Tumoral MGMT content predicts survival in patients with aggressive pituitary tumors and pituitary carcinomas given treatment with temozolomide",

keywords = "Adult, Aged, Antineoplastic Agents, Alkylating/therapeutic use, DNA Modification Methylases/metabolism, DNA Repair Enzymes/metabolism, Female, Humans, Male, Middle Aged, Pituitary Neoplasms/drug therapy, Prognosis, Survival Rate, Temozolomide/therapeutic use, Treatment Outcome, Tumor Suppressor Proteins/metabolism",

author = "D. Bengtsson and Schr{\o}der, {H. D.} and K. Berinder and D. Maiter and C. Hoybye and O. Ragnarsson and U. Feldt-Rasmussen and {Krogh Rasmussen}, Rasmussen and {van der Lely}, A. and M. Petersson and G. Johannsson and M. Andersen and P. Burman",

year = "2018",

month = dec,

doi = "10.1007/s12020-018-1751-9",

language = "English",

volume = "62",

pages = "737–739",

journal = "Endocrine",

issn = "1355-008X",

publisher = "Humana Press",

number = "3",

}

Bengtsson, D, Schrøder, HD, Berinder, K, Maiter, D, Hoybye, C, Ragnarsson, O, Feldt-Rasmussen, U, Krogh Rasmussen, R, van der Lely, A, Petersson, M, Johannsson, G, Andersen, M & Burman, P 2018, 'Tumoral MGMT content predicts survival in patients with aggressive pituitary tumors and pituitary carcinomas given treatment with temozolomide', Endocrine, vol. 62, no. 3, pp. 737–739. https://doi.org/10.1007/s12020-018-1751-9

TY - JOUR

T1 - Tumoral MGMT content predicts survival in patients with aggressive pituitary tumors and pituitary carcinomas given treatment with temozolomide

AU - Bengtsson, D.

AU - Schrøder, H. D.

AU - Berinder, K.

AU - Maiter, D.

AU - Hoybye, C.

AU - Ragnarsson, O.

AU - Feldt-Rasmussen, U.

AU - Krogh Rasmussen, Rasmussen

AU - van der Lely, A.

AU - Petersson, M.

AU - Johannsson, G.

AU - Andersen, M.

AU - Burman, P.

PY - 2018/12

Y1 - 2018/12

KW - Adult

KW - Aged

KW - Antineoplastic Agents, Alkylating/therapeutic use

KW - DNA Modification Methylases/metabolism

KW - DNA Repair Enzymes/metabolism

KW - Female

KW - Humans

KW - Male

KW - Middle Aged

KW - Pituitary Neoplasms/drug therapy

KW - Prognosis

KW - Survival Rate

KW - Temozolomide/therapeutic use

KW - Treatment Outcome

KW - Tumor Suppressor Proteins/metabolism

U2 - 10.1007/s12020-018-1751-9

DO - 10.1007/s12020-018-1751-9

M3 - Journal article

C2 - 30246233

AN - SCOPUS:85053657322

SN - 1355-008X

VL - 62

SP - 737

EP - 739

JO - Endocrine

JF - Endocrine

IS - 3

ER -